November 2013, Vol 2, No 7
PMO Proudly Announces Dr Sanjiv S.Agarwala to Join Dr Al Benson as Co-Editor in Chief
Benson III, MD
It is with great pleasure that I announce our newly appointed Co-Editor in Chief, Sanjiv S. Agarwala. Dr Agarwala joins me in this position to bring the oncology community the latest advances in our ability to personalize care for patients.
Dr Agarwala is Professor of Medicine at Temple University School of Medicine in Philadelphia and Chief of Oncology & Hematology at St. Lukeâs Cancer Center in Bethlehem, Pennsylvania.
Dr Agarwala is an internationally recognized investigator in the field of melanoma and immunotherapy. He has published on a variety of therapeutic approaches to melanoma and has led promising clinical trials of immunotherapy and targeted therapy of melanoma. He received his degree and completed an internship and residency at the Seth G.S. Medical College and King Edward Memorial Hospital in Bombay, India. He also completed residency training in internal medicine and a fellowship in hematology-oncology at the University of Pittsburgh School of Medicine.
We are delighted to work with him at PMO, and it is my pleasure to welcome him in this capacity.
Al B. Benson III, MD
It is my pleasure to write to you as Co-Editor in Chief of PMO alongside Dr Benson. The world of oncology has seen more promise, change, and improvements in the past decade than ever before. The Editors and Staff of PMO are proud to be part of that change by meaningfully disseminating potentially life-changing information to our readership. In my new capacity, I hope to continue this tradition by featuring articles within our pages that provide in-depth information about emerging therapies, various genetic mutations, protein expressions, and other indicators and their implications for treatment in different subsets of patients with cancer.
It is our hope that these pages assist you in providing optimal care for your patients. I look forward to serving you.
Sanjiv S. Agarwala, MD
The ânew taxonomyâ of breast cancer and molecular subtyping of tumors are âmaking clinical senseâ to oncologists, but molecular tools that describe these cancers are still not ready for routine use, according to Joyce OâShaughnessy, MD, of Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas. At the 2013 Breast [ Read More ]
Multiple Myeloma and the MMRF CoMMpass Study: Revolutionizing Clinical Trial Data Dissemination A Panel Discussion With the Researchers
The Multiple Myeloma Research Foundation (MMRF) launched the CoMMpass study in 2011 to uncover the molecular segments and variations in multiple myeloma. This study, the cornerstone of the larger MMRF Personalized Medicine Initiative, is designed to profile multiple myeloma in a way that no other myeloma trial has attempted, by [ Read More ]